Latest News-SIRNAOMIC LTD Mediaroom_Page

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Com...

2023-06-05 19:12 3145

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Co...

2023-06-02 00:06 7052

Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd...

2023-05-17 21:13 3225

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" ...

2023-04-28 00:29 3131

Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Study commences following green light from the U.S. FDA for Investigational New Drug Application H...

2023-04-12 16:25 2658

Sirnaomics Announces 2022 Annual Results

Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therap...

2023-03-28 19:26 6968

Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics L...

2023-03-20 23:27 2563

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 7, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "C...

2023-02-07 16:34 3028

Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "C...

2023-02-01 15:00 3633

Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

First three out of five cohorts pass safety requirements, allowing the Company to dose additional c...

2022-12-21 00:39 3379

Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ

Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses o...

2022-12-14 23:47 2463

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sir...

2022-12-14 01:41 4018

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sir...

2022-12-14 01:40 2160

Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment

Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 ...

2022-11-08 05:13 2491

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA LeadersUSA Con...

2022-10-19 14:55 2116

Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference

GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics Ltd

2022-09-20 22:40 3031

Sirnaomics to Present at 3rd Annual Jefferies Asia Forum

GAITHERSBURG, Md. and SUZHOU, China, Sept. 7, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or...

2022-09-07 11:32 3309

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Data showed an excellent safety profile with no adverse events among the five subjects treated. Com...

2022-08-29 15:59 2886

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" o...

2022-08-26 21:54 10029

Sirnaomics Becoming A Constituent of Hang Seng Family of Indexes

HONG KONG, Aug. 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code...

2022-08-22 08:33 2854